.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,990,100

« Back to Dashboard

Claims for Patent: 5,990,100

Title: Composition and method for treatment of psoriasis
Abstract:Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.
Inventor(s): Rosenberg; E. William (Memphis, TN), Glenn; Thomas M. (Mobile, AL), Skinner, Jr.; Robert B. (Memphis, TN), Noah; Patricia W. (Germantown, TN)
Assignee: Panda Pharmaceuticals, L.L.C. (Memphis, TN) The University of Tennessee Research Corporation (Knoxville, TN)
Application Number:09/143,146
Patent Claims: 1. A pharmaceutical composition for use in the treatment of psoriasis comprising (a) 0.0001 to 30 weight percent of an anti-psoriatic agent selected from the group consisting of corticosteroids, calcipotriol, retinoids, tar, and mixtures thereof and (b) 15 to 97 weight percent isopropyl myristate, said component (a) being present in an effective anti-psoriatic weight percent, said pharmaceutical composition being a liquid and being in a form suitable for topical administration to a human.

2. A composition according to claim 1, said composition being at least 25 weight percent isopropyl myristate.

3. A composition according to claim 2, said composition being at least 40 weight percent isopropyl myristate.

4. A composition according to claim 2, said composition being 38-60 weight percent isopropyl myristate.

5. A composition according to claim 1, said composition being at least 38 weight percent isopropyl myristate, at least 40 weight percent of said composition being formed from water, ethanol, isopropyl alcohol, or any combination thereof.

6. A composition according to claim 1, said composition being 38-60 weight percent isopropyl myristate, 1.5-10 weight percent water, and 35-60 weight percent ethanol.

7. A method of treating psoriasis comprising topically administering to a human having psoriasis a pharmaceutical composition comprising (a) 0.0001 to 30 weight percent of an anti-psoriatic agent selected from the group consisting of corticosteroids, calcipotriol, retinoids, tar, and mixtures thereof and (b) 15 to 97 weight percent isopropyl myristate, said component (a) being present in an effective anti-psoriatic weight percent, said pharmaceutical composition being a liquid and being in a form suitable for topical administration to a human.

8. A composition according to claim 1, said composition comprising 0.001-5 weight percent corticosteroid.

9. A composition according to claim 8, wherein said composition is at least 25 weight percent isopropyl myristate.

10. A composition according to claim 9, wherein said composition is at least 35 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

11. A composition according to claim 10, wherein said alcohol is ethanol, isopropyl alcohol, or a mixture thereof.

12. A composition according to claim 11, said composition being 38-60 weight percent isopropyl myristate, 1.5-10 weight percent water, and 35-60 weight percent ethanol.

13. A composition according to claim 1, wherein said component (a) anti-psoriatic agent is present at 0.005 to 10 weight percent.

14. A composition according to claim 1, wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

15. A composition according to claim 1, said composition comprising 0.0001-0.1 weight percent calcipotriol.

16. A composition according to claim 15, wherein said composition is at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

17. A composition according to claim 1, said composition comprising 0.001-5 weight percent of a corticosteroid other than hydrocortisone.

18. A composition according to claim 17, wherein said composition is at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

19. A composition according to claim 1, wherein at least 40 weight percent of said composition is formed from water, ethanol, isopropyl alcohol, or any combination thereof.

20. A composition according to claim 1, said composition being 30-55 weight percent isopropyl myristate.

21. A composition according to claim 1, said composition consisting essentially of said anti-psoriatic agent, said isopropyl myristate, and at least 40 weight percent water, alcohol or a mixture of water and alcohol.

22. A composition according to claim 21, wherein said anti-psoriatic agent is a corticosteroid other than hydrocortisone.

23. A composition according to claim 21, wherein said anti-psoriatic agent is calcipotriol.

24. A composition according to claim 1, said composition consisting of said anti-psoriatic agent, said isopropyl myristate, surfactant, and at least 40 weight percent of a mixture of water and alcohol.

25. A composition according to claim 24, wherein said anti-psoriatic agent is a corticosteroid other than hydrocortisone.

26. A method according to claim 7, wherein said composition is at least 25 weight percent isopropyl myristate.

27. A method according to claim 7, wherein said composition is at least 40 weight percent isopropyl myristate.

28. A method according to claim 7, wherein said composition is 30-60 weight percent isopropyl myristate.

29. A method according to claim 7, wherein said composition is at least 38 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, ethanol, isopropyl alcohol, or any combination thereof.

30. A method according to claim 7, wherein said composition comprises 38-60 weight percent isopropyl myristate, 1.5-10 weight percent water, and 35-60 weight percent ethanol.

31. A method according to claim 7, wherein said composition comprises 0.001-5 weight percent corticosteroid and at least 35 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

32. A method according to claim 7, wherein said composition comprises 0.0001-0.1 weight percent calcipotriol and at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

33. A method according to claim 7, wherein said composition comprises 0.001-5 weight percent of a corticosteroid other than hydrocortisone, wherein said composition comprises at least 25 weight percent isopropyl myristate and wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

34. A method according to claim 7, wherein at least 40 weight percent of said composition is formed from water, alcohol, or any combination thereof.

35. A method according to claim 7, wherein said composition consists essentially of said anti-psoriatic agent, said isopropyl myristate, and at least 40 percent water, alcohol, or a mixture of water and alcohol.

36. A method according to claim 35, wherein said anti-psoriatic agent is calcipotriol or a corticosteroid other than hydrocortisone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc